Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Depreciation & Amortization (CF) (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 25.53% year-over-year to $2.8 million, compared with a TTM value of $10.6 million through Dec 2025, up 26.18%, and an annual FY2025 reading of $10.6 million, up 26.18% over the prior year.
  • Depreciation & Amortization (CF) was $2.8 million for Q4 2025 at Treace Medical Concepts, up from $2.8 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.8 million in Q4 2025 and bottomed at $100000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.4 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 74.75% in 2021, then surged 300.0% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $285000.0 in 2021, then skyrocketed by 221.75% to $917000.0 in 2022, then skyrocketed by 92.91% to $1.8 million in 2023, then increased by 26.46% to $2.2 million in 2024, then increased by 25.53% to $2.8 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for TMCI at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.6 million in Q2 2025.